University of Pennsylvania

Valorisation-Recherche, Societe En Commandite

Other

Institut De Recherches Cliniques De Montreal

Institute for Molecular Medicine, Inc.

Uni Vax

Oncomune, LLC

Michael Agadjanyan

Anahit Ghochikyan

David B Weiner

Mark J Holterman

Rafick P Sekaly

Jong J Kim

The disclosure provides methods of treating tauopathies (e.g. Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia with Parkinsonism linked to chromosome 17, Pick's Disease, Progressive Supranuclear Palsy, Dementia Pugilistica, Down's Syndrome and others) by administering humanized antibodies. The disclosure also provides the anti-tau humanized antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).

Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies

Disclosed are compositions, comprising one or more immunogens, wherein each immunogen comprises at least two regions, wherein one region comprises at least one amyloid-&#x3b2; (A&#x3b2;) B cell epitope or at least one Tau B cell epitope or at least one &#x3b1;-synuclein B cell epitope or combinations thereof, and a second region comprises at least one foreign T helper cell (Th) epitope, and usually multiple foreign Th epitopes. Methods of making and using the compositions are also disclosed.

Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein

Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.

Mutant human CD80 and compositions for and methods of making and using the same

Polynucleotides encoding a nonfunctional mutant form of the Brother of Regulator of Imprinted Sites (BORIS) molecule, nonfunctional mutated BORIS protein, polypeptide or peptide and modified protein forms of BORIS are described. These molecules are used as a therapeutic vaccine against cancer.

Cancer vaccine based on brother of regulator of imprinted sites molecule (BORIS)

Methods of inducing an immune response against an immunogen in an individual are disclosed. The methods comprise administering to the individual, one or more nucleic acid molecules that comprise a nucleotide sequence that encodes an immunogen and a nucleotide sequence that encodes an Major Histocompatibility Complex antigen. The nucleotide sequences that encode the immunogen and the Major Histocompatibility Complex antigen are expressed when taken up by cells of the individual and an immune response against the immunogen is induced in the individual. Methods of reducing rejection of unmatched donor cells, tissue or organ in an individual undergoing cell, tissue or organ transplantation are disclosed. The methods comprise administering to the individual, one or more nucleic acid molecules that comprise a nucleotide sequence that encodes a death signal or toxin and a nucleotide sequence that encodes a Major Histocompatibility Complex antigen that is matched to the donor cells, tissue or organ. The nucleotide sequences that encode the Major Histocompatibility Complex antigen and death signal or toxin are expressed when taken up by cells of the individual. T cell death through interaction with the death signal or toxin results in a reduction of rejection of unmatched donor cells, tissue or organ. Methods of reducing a dominant immune response in an individual and methods of expanding a subpopulation of T cells associated with a specific immune response are also described. Plasmids and compositions comprising plasmids useful for practicing the method are described.

Vaccines and gene therapy compositions and methods of making and using the same

Cancer vaccine based on brother of regulator of imprinted sites molecule

Nucleic acids encoding mutant human CD80 and compositions comprising the same

Growing community of inventors

Huntington Beach, CA, United States of America

Michael Agadjanyan